Myfortic FDA Approval History
FDA Approved: Yes (First approved February 27, 2004)
Brand name: Myfortic
Generic name: mycophenolic acid
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Organ Transplant, Rejection Prophylaxis
Myfortic is an enteric-coated formulation of mycophenolic acid for use in combination with cyclosporine and corticosteroids to prevent organ rejection in kidney transplant patients.
Development timeline for Myfortic
| Date | Article |
|---|---|
| Feb 27, 2004 | Approval Myfortic Novartis Pharma AG - Treatment for Prevention of Organ Rejection |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.